Zachary Roberts Sells 35,700 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 35,700 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the transaction, the executive vice president directly owned 581,166 shares of the company’s stock, valued at $1,028,663.82. The trade was a 5.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Zachary Roberts also recently made the following trade(s):

• On Wednesday, January 21st, Zachary Roberts sold 26,269 shares of Allogene Therapeutics stock. The stock was sold at an average price of $1.56, for a total transaction of $40,979.64.

Allogene Therapeutics Stock Down 9.4%

NASDAQ ALLO opened at $1.63 on Friday. The company has a market capitalization of $366.31 million, a price-to-earnings ratio of -1.66 and a beta of 0.60. Allogene Therapeutics, Inc. has a twelve month low of $0.86 and a twelve month high of $3.78. The stock’s 50-day simple moving average is $1.52 and its two-hundred day simple moving average is $1.32.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04. On average, equities analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. UBS Group assumed coverage on shares of Allogene Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $8.00 price objective for the company. Citigroup raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Friday, January 9th. Wall Street Zen raised Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $8.40.

Institutional Trading of Allogene Therapeutics

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its position in shares of Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after buying an additional 3,747,397 shares in the last quarter. Millennium Management LLC increased its position in Allogene Therapeutics by 125.6% in the third quarter. Millennium Management LLC now owns 3,390,026 shares of the company’s stock worth $4,204,000 after purchasing an additional 1,887,302 shares during the last quarter. Two Sigma Investments LP raised its stake in Allogene Therapeutics by 109.7% during the third quarter. Two Sigma Investments LP now owns 3,383,644 shares of the company’s stock valued at $4,196,000 after purchasing an additional 1,770,419 shares in the last quarter. UBS Group AG increased its stake in Allogene Therapeutics by 75.1% during the third quarter. UBS Group AG now owns 3,571,157 shares of the company’s stock worth $4,428,000 after acquiring an additional 1,532,238 shares during the last quarter. Finally, Primecap Management Co. CA raised its position in Allogene Therapeutics by 23.8% during the third quarter. Primecap Management Co. CA now owns 7,079,308 shares of the company’s stock valued at $8,778,000 after purchasing an additional 1,360,168 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

More Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Company-reported progress in its CAR‑T trials and an update indicating an extended cash runway sparked a recent rally by reducing near‑term financing risk and keeping clinical milestones on the radar. Article Title
• Neutral Sentiment: Allogene announced participation in two investor conferences in Q1 2026 — a standard IR activity that gives the company chances to update investors but is not itself a catalyst for immediate clinical progress. Article Title
• Neutral Sentiment: Broader sector commentary highlights rapid innovation in immunotherapy and AI-driven oncology R&D — a positive backdrop for Allogene but not an immediate company‑specific driver. Article Title
• Negative Sentiment: Multiple insider sales were filed for Feb. 2 (including CEO David D. Chang selling ~95,269 shares at ~$1.80 and several C‑suite/SVP sales reported at ~$1.72–1.77). While each sale is a modest percentage of individual holdings, the cluster of senior executive sales is likely increasing selling pressure and contributing to today’s pullback. Article Title

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.